Cardiovascular Systems ROE 2006-2019 | CSII

Current and historical return on equity (ROE) values for Cardiovascular Systems (CSII) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Cardiovascular Systems ROE for the three months ending March 31, 2019 was 1.47%.
Cardiovascular Systems ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2019-03-31 $0.00B $0.14B 1.46%
2018-12-31 $0.00B $0.14B 0.75%
2018-09-30 $0.00B $0.13B 0.77%
2018-06-30 $0.00B $0.13B 1.59%
2018-03-31 $-0.00B $0.13B -0.82%
2017-12-31 $-0.00B $0.12B -2.53%
2017-09-30 $-0.00B $0.12B -1.73%
2017-06-30 $-0.00B $0.12B -1.79%
2017-03-31 $-0.01B $0.11B -7.46%
2016-12-31 $-0.03B $0.11B -27.75%
2016-09-30 $-0.05B $0.10B -42.15%
2016-06-30 $-0.06B $0.10B -49.23%
2016-03-31 $-0.06B $0.10B -48.68%
2015-12-31 $-0.05B $0.12B -35.96%
2015-09-30 $-0.04B $0.13B -27.09%
2015-06-30 $-0.03B $0.14B -22.84%
2015-03-31 $-0.03B $0.14B -23.01%
2014-12-31 $-0.03B $0.15B -21.85%
2014-09-30 $-0.04B $0.15B -24.18%
2014-06-30 $-0.04B $0.15B -27.22%
2014-03-31 $-0.03B $0.16B -29.73%
2013-12-31 $-0.03B $0.16B -32.40%
2013-09-30 $-0.03B $0.07B -45.02%
2013-06-30 $-0.02B $0.07B -49.23%
2013-03-31 $-0.02B $0.07B -55.00%
2012-12-31 $-0.02B $0.03B -73.39%
2012-09-30 $-0.02B $0.03B -70.59%
2012-06-30 $-0.02B $0.03B -70.83%
2012-03-31 $-0.01B $0.02B -65.12%
2011-12-31 $-0.01B $0.02B -57.14%
2011-09-30 $-0.01B $0.02B -50.63%
2011-06-30 $-0.01B $0.02B -56.34%
2011-03-31 $-0.01B $0.02B -71.64%
2010-12-31 $-0.02B $0.02B -100.00%
2010-09-30 $-0.02B $0.02B -118.92%
2010-06-30 $-0.02B $0.02B -111.63%
2010-03-31 $-0.03B $0.02B -106.12%
2009-12-31 $0.00B $0.02B 10.53%
2009-06-30 $0.00B $0.03B 7.34%
2009-03-31 $-0.01B $0.03B -55.70%
2008-06-30 $-0.06B -130.23%
2008-03-31 $0.01B $0.07B 11.35%
2007-06-30 $0.03B $0.11B 47.43%
2007-03-31 $-0.02B $0.06B -52.17%
2006-09-30 $-0.04B $0.08B -86.86%
2006-06-30 $-0.04B $0.04B -176.84%
2006-03-31 $-0.04B -303.70%
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $1.537B $0.217B
Cardiovascular Systems, Inc., formerly known as Replidyne Inc., is headquartered in Saint Paul, Minnesota. It is a medical device company focusing on developing and commercializing interventional treatment systems for vascular disease. Its initial product, the Diamondback 360? Orbital Atherectomy System, is a minimally invasive catheter system for the treatment of peripheral arterial disease; and a range of plaque types, including calcified vessel lesions. The Diamondback 360? removes soft and calcified plaque in plaque-lined vessels through the orbital rotation of a diamond grit coated offset crown. The company refined its `orbital` technology to address the growing market need of providing a safer more effective atherectomy device.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $148.050B 28.74
Medtronic (MDT) Ireland $133.110B 19.01
Stryker (SYK) United States $77.009B 27.48
Boston Scientific (BSX) United States $58.755B 28.17
Baxter (BAX) United States $41.655B 26.25
EssilorLuxottica Societe Anonyme (ESLOY) France $29.025B 0.00
Coloplast (CLPBY) Denmark $25.553B 40.79
Zimmer Biomet Holdings (ZBH) United States $24.699B 15.87
Lonza Group Ag (LZAGY) Switzerland $24.641B 0.00
Terumo (TRUMY) Japan $23.393B 26.90
Smith & Nephew SNATS (SNN) United Kingdom $19.003B 0.00
ResMed (RMD) United States $17.837B 34.08
Sunny Optical Technology (SNPTF) China $12.027B 0.00
Canopy Growth (CGC) Canada $11.829B 0.00
Bio-Rad Laboratories (BIO) United States $9.215B 48.85
William Demant Holdings (WILYY) Denmark $7.651B 0.00
Insulet (PODD) United States $7.176B 522.83
Perrigo (PRGO) Ireland $7.039B 11.90
Hill-Rom Holdings (HRC) United States $6.945B 21.06
Aurora Cannabis (ACB) Canada $6.865B 67.70
GN STORE NORD (GNNDY) Denmark $6.409B 32.73
Haemonetics (HAE) United States $6.279B 51.26
GW Pharmaceuticals (GWPH) United Kingdom $5.201B 0.00
ICU Medical (ICUI) United States $5.129B 30.60
Neogen (NEOG) United States $3.284B 53.39
NuVasive (NUVA) United States $2.961B 24.18
Hutchison China MediTech (HCM) China $2.957B 0.00
Agios Pharmaceuticals (AGIO) United States $2.654B 0.00
National Vision Holdings (EYE) United States $2.458B 52.37
Quidel (QDEL) United States $2.284B 23.70
Aphria (APHA) $1.561B 0.00
Phibro Animal Health (PAHC) United States $1.234B 18.49
AtriCure (ATRC) United States $1.212B 0.00
VAREX IMAGING (VREX) United States $1.174B 24.92
Lantheus Holdings (LNTH) United States $1.078B 28.62
NanoString Technologies (NSTG) United States $1.036B 0.00
PetIQ (PETQ) United States $0.971B 23.59
MacroGenics (MGNX) United States $0.775B 0.00
Omeros (OMER) United States $0.770B 0.00
Cerus (CERS) United States $0.759B 0.00
Eagle Pharmaceuticals (EGRX) United States $0.755B 21.17
Quanterix (QTRX) United States $0.742B 0.00
TG Therapeutics (TGTX) United States $0.704B 0.00
LeMaitre Vascular (LMAT) United States $0.574B 27.78
Surmodics (SRDX) United States $0.544B 79.10
OraSure Technologies (OSUR) United States $0.532B 24.51
Meridian Bioscience (VIVO) United States $0.487B 14.90
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.392B 0.00
Vapotherm (VAPO) United States $0.354B 0.00
Utah Medical Products (UTMD) United States $0.321B 22.26
BioLife Solutions (BLFS) United States $0.318B 99.59
Zynex (ZYXI) United States $0.277B 28.53
Bovie Medical (APYX) United States $0.237B 0.00
Cytosorbents (CTSO) United States $0.227B 0.00
Owens & Minor (OMI) United States $0.200B 4.24
Chimerix (CMRX) United States $0.188B 0.00
Rockwell Medical (RMTI) United States $0.175B 0.00
United Health Products (UEEC) United States $0.171B 0.00
Female Health (VERU) United States $0.145B 0.00
Fonar (FONR) United States $0.139B 7.30
Chembio Diagnostics (CEMI) United States $0.098B 0.00
United-Guardian (UG) United States $0.093B 20.56
Surface Oncology (SURF) United States $0.074B 0.00
Trinity Biotech (TRIB) Ireland $0.058B 20.00
Oramed Pharmaceuticals (ORMP) United States $0.057B 0.00